Captopril-AKOS - instructions for use, dose, side effects, contraindications

Tablets are white or white with a creamy shade of color with a characteristic odor, a flat-cylindrical shape with a bevel. A slight "marble" is allowed.

Pharmacotherapeutic group:Angiotensin converting enzyme inhibitor

ATX: & nbsp

C.09.A.A.01 Captopril

Pharmacodynamics:

Reduces the formation of angiotensin II and angiotensin I. Reduction in angiotensin II leads to a direct reduction in the release of aldosterone. This reduces the overall peripheral vascular resistance, blood pressure, post- and preload on the heart. Expands arteries more than veins. It causes a decrease in the degradation of bradykinin (one of the effects of ACE) and an increase in the synthesis of prostaglandin.

The hypotensive effect does not depend on the plasma renin activity, the decrease in arterial pressure is noted at a normal and even lowered level of the hormone, which is due to the effect on tissue renin-angiotensin systems. Strengthens coronary and renal blood flow.

With prolonged use reduces the severity of myocardial hypertrophy and the walls of arteries of resistive type. Improves the blood supply of the ischemic myocardium. Reduces the aggregation of platelets. Promotes content reduction Na+ in patients with heart failure.

Reduction of blood pressure in contrast to direct vasodilators (hydralazine, minoxidil, etc.) is not accompanied by reflex tachycardia and leads to a decrease in myocardial oxygen demand. With heart failure in an adequate dose does not affect the value of blood pressure.

The maximum decrease in blood pressure after oral administration is observed after 60-90 minutes. The duration of the hypotensive effect is dose-dependent and reaches optimal values within a few weeks.

Pharmacokinetics:

Absorption - fast, reaches 75% (food intake decreases by 30-40%), bioavailability - 35-40% (the effect of "first pass" through the liver). Connection with plasma proteins (mainly with albumins) - 25-30%; the maximum concentration in the blood plasma (114 ng / ml) with oral intake - 30-90 min. Through the blood-brain barrier and placental barrier penetrates poorly (less than 1%).

Metabolized in the liver with the formation of disulfide dimer captopril and captopril-cysteine disulfide. Metabolites are pharmacologically inactive.

The half-life is 3 hours. It is excreted by the kidneys 95% (40-50% unchanged), the rest in the form of metabolites. It is secreted with mother's milk. Four hours after a single dose in urine contains 38% of unchanged captopril and 28% in the form of metabolites, after 6 hours - only in the form of metabolites; in daily urine - 38% of unchanged captopril and 62% - in the form of metabolites.

Half-life with renal failure is 3.5-32 hours. Cumulates in chronic renal failure.

Indications:

Arterial hypertension, incl. Renovascular.

Chronic heart failure (in complex therapy).

Violations of left ventricular function after a myocardial infarction with a clinically stable condition; Diabetic nephropathy in the background of type 1 diabetes mellitus (for albuminuria more than 30 mg / day).

Contraindications:

Increased sensitivity to the drug and other ACE inhibitors, angioedema (in the background of ACE inhibitors, including a history of), expressed impaired renal or hepatic function, hyperkalemia, bilateral renal artery stenosis or artery stenosis only kidneys with progressive azotemia, condition after transplantation kidneys, stenosis of the aortic aorta and similar changes that hinder the outflow of blood, pregnancy, lactation, age 18 years.

Carefully:

Severe autoimmune diseases (especially SLE or scleroderma), inhibition of bone marrow hematopoiesis (risk of neutropenia and agranulocytosis), cerebral ischemia, diabetes (elevated risk of hyperkalemia), patients on gemodialeze diet with sodium limitation, primary hyperaldosteronism, ischemic heart disease , conditions accompanied by a decrease in the volume of circulating blood (including diarrhea, vomiting), and advanced age.

Dosing and Administration:

Captopril-AKOS is prescribed orally for 1 hour before meals. The dosage regimen is set individually.

With arterial hypertension treatment is started with the lowest effective dose of 12.5 mg 2 times a day (rarely with 6.25 mg 2 times a day). Pay attention to the tolerability of the first dose during the first hour. If at the same time arterial hypotension develops, the patient should be transferred to a horizontal position (this reaction to the first dose should not serve as an obstacle to further therapy). If necessary, the dose gradually (with an interval of 2-4 weeks) is increased to achieve the optimal effect. With mild or moderate arterial hypertension, the usual maintenance dose is 25 mg 2 times a day; the maximum dose is 50 mg twice a day. In severe arterial hypertension, the maximum dose is 50 mg 3 times a day. The maximum daily dose is 150 mg.

In elderly patients the initial dose is 6.25 mg twice a day.

With chronic heart failure prescribe along with diuretics and / or in combination with digitalis preparations (to avoid initial excessive decrease in blood pressure, prior to the appointment of Captopril-ACOS diuretic is canceled or reduced dose). The initial dose is 6.25 mg or 12.5 mg 3 times a day, if necessary, increase the dose to 25 mg 3 times a day. The maximum daily dose is 150 mg.

In cases of violations of left ventricular function after a previous myocardial infarction in patients in a clinically stable state, the use of Captopril-ACOS can begin as early as 3 days after myocardial infarction. The initial dose is 6.25 mg / day, then the daily dose can be increased to 37.5-75 mg for 2-3 doses (depending on the drug's tolerance). If necessary, the dose is gradually increased to a maximum daily dose of 150 mg / day.

With the development of arterial hypotension, a dose reduction may be required. Subsequent attempts to apply a maximum daily dose of 150 mg should be based on tolerability of patients with Captopril-ACOS.

With diabetic nephropathy appoint a daily dose of 75-150 mg / day for 2-3 doses. With insulin-dependent diabetes with microalbuminuria (albumin release 30-300 mg per day), the dose of the drug is 50 mg 2 times a day. With a total protein clearance of more than 500 mg per day, the drug is effective at a dose of 25 mg 3 times a day.

With a moderate degree of impaired renal function (KK - not less than 30 ml / min / 1.73 m 2) Captopril-AKOS can be administered at a dose of 75-100 mg / day. With a more pronounced degree of renal dysfunction (CC - less than 30 ml / min / 1.73 m 2), the initial dose should not exceed 12.5 mg / day; further,if necessary, the dose of Captopril-AKOS is gradually increased after sufficiently long intervals of time, but use a daily dose of the drug less than in the case of arterial hypertension.

If necessary, additionally prescribed loop diuretics, and not diuretics thiazide series.

Side effects:

From the side of the cardiovascular system: tachycardia, lowering of arterial pressure, orthostatic hypotension, peripheral edema.

From the nervous system: dizziness, headache, fatigue, asthenia, paresthesia, ataxia, drowsiness, visual impairment.

From the respiratory system: dry cough, pulmonary edema, bronchospasm.

From the urinary system: impaired renal function.

From the side of water-electrolyte exchange: hyperkalemia, hyponatremia (most often with a salt-free diet and simultaneous intake of diuretics), proteinuria, elevated levels of urea nitrogen in the blood, creatinine, acidosis.

On the part of the organs of hematopoiesis: neutropenia, anemia, thrombocytopenia, agranulocytosis.

Allergic reactions: angioedema, "hot flashes" of blood to the skin of the face, fever, skin rash (maculopapular,less often - vesicular or bullous character), itching, photosensitivity, serum sickness, lymphadenopathy, in rare cases - the appearance of antinuclear antibodies in the blood.

From the digestive system: loss of taste, dry mouth, decreased appetite, stomatitis, dyspepsia, nausea, abdominal pain, constipation or diarrhea, increased activity of "liver" enzymes, hyperbilirubinemia; signs of hepatocellular injury (hepatitis) and cholestasis (in rare cases); pancreatitis (in isolated cases), gingival hyperplasia, intestinal edema.

Other: general weakness, swelling of the legs.

Overdose:

Symptoms: a marked decrease in blood pressure, including collapse, myocardial infarction, acute cerebrovascular accident, thromboembolic complications.

Treatment: lay the patient with raised lower limbs; measures aimed at restoring blood pressure (increase in the volume of circulating blood, including intravenous infusion of 0.9% sodium chloride), symptomatic therapy.

Possible use of hemodialysis; peritoneal dialysis - ineffective.

Interaction:

Increases the concentration of digoxin in the plasma by 15-20%.

Increases the bioavailability of propranolol.

Cimetidine, slowing the metabolism in the liver, increases the concentration of captopril in the blood plasma.

Hypotensive effect weakens non-steroidal anti-inflammatory drugs (NSAIDs) (delay Na+ and reduced prostaglandin synthesis), especially against a background of low renin concentration, and estrogen (Na + delay).

Combination with thiazide diuretics, vasodilators (minoxidil), verapamil, beta-adrenoblockers, tricyclic antidepressants, ethanol enhances the hypotensive effect.

Combined use with potassium-sparing diuretics (eg triamterene, spironolactone, amyloride), potassium preparations, cyclosporine, milk with low salt content (can contain K + up to 60 mmol / l), potassium supplements, salt substitutes (contain significant amounts of K +) increases the risk of hyperkalemia.

Slows the excretion of lithium preparations.

When captopril is prescribed against the background of taking allopurinol or procainamide, the risk of developing Stevens-Johnson syndrome and immunosuppressive action is increased.

The use of captopril in patients taking immunosuppressants (for example, azathioprine or cyclophosphamide), increases the risk of hematological disorders.

Special instructions:

Before starting, and also regularly during the treatment with Captopril-AKOS, kidney function should be monitored. Patients with chronic heart failure are treated under close medical supervision. Against the background of prolonged use of Captopril-AKOS, approximately 20% of patients have a stable increase in serum urea and serum creatinine by more than 20%, compared with the norm or the baseline value. Less than 5% of patients, especially in severe nephropathies, require discontinuation of treatment due to increased creatinine concentrations. In patients with arterial hypertension with the use of Captopril-AKOS, severe arterial hypotension is observed only in rare cases; the likelihood of developing this condition increases with a loss of fluid and salt loss (for example, after intensive treatment with diuretics), in patients with chronic cardiac insufficiency or who are on dialysis.The possibility of a sharp drop in blood pressure can be minimized by first canceling (for 4-7 days) a diuretic or increasing the intake of sodium chloride (about a week before the start of the procedure) or by administering captopril at the start of treatment in small doses (6.25- 12.5 mg / day). When therapy in outpatient settings, warn the patient about the possible appearance of symptoms of an infection requiring a follow-up medical examination, a clinical and laboratory examination. In the first 3 months. therapies monitor the number of blood leukocytes on a monthly basis, then - once every 3 months; in patients with autoimmune diseases in the first 3 months. - every 2 weeks, then every 2 months. If the number of white blood cells is less than 4000 / μL, a general blood test is performed, below 1000 / μL - the drug is stopped. If the first symptoms of a secondary infection occur against a background of myeloid hypoplasia, an extensive blood test should be performed immediately. It is necessary to exclude self-termination of the drug and an independent significant increase in the intensity of physical exertion. In some cases, against the background of the use of ACE inhibitors, incl.captopril, there is an increase in the concentration of potassium in the blood serum. The risk of hyperkalemia in the use of ACE inhibitors is increased in patients with renal insufficiency and diabetes mellitus, as well as taking potassium-sparing diuretics, potassium preparations or other drugs that cause an increase in the concentration of potassium in the blood (for example, heparin). You should avoid the simultaneous use of potassium-sparing diuretics and potassium preparations. When hemodialysis in patients receiving Captopril-ACOS, dialysis membranes with high permeability (for example, AN69) should be avoided, since in such cases the risk of anaphylactoid reactions increases. In case of development of angioedema, the drug is canceled and careful medical supervision and symptomatic therapy are carried out. When taking Captopril-AKOS, a false positive reaction can be observed when analyzing urine for acetone.

Be wary appoint patients who are on a low-salt or salt-free diet (an increased risk of arterial hypotension) and hyperkalemia.

Effect on the ability to drive transp. cf. and fur:During the period of treatment it is necessary to refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions. possibly dizziness, especially after taking the initial dose.

Form release / dosage:

Tablets 25 mg.

Packaging:For 10 or 25 tablets in a contour mesh package.

1, 2, 3 or 4 contour cells with instructions for use are placed in a pack of cardboard.

Storage conditions:

In a dry place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiration date indicated on the label.

Terms of leave from pharmacies:On prescription

Registration number:P N002388 / 01

Date of registration:06.05.2008 / 19.11.2008

Expiration Date:Unlimited

The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia

Manufacturer: & nbsp

SYNTHESIS, OJSC Russia

Representation: & nbspSYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products SYNTHESIS JSC Joint-Stock Kurgan Society of Medical Preparations and Products Russia

Information update date: & nbsp06.12.2017

Illustrated instructions

Instructions

Captopril-AKOS (Captopril-AKOS)